MX2010008466A - Formulaciones de liberación modificada de inhibidores de 3-hidroxi-3-metilglutaril-coenzima a reductasa. - Google Patents
Formulaciones de liberación modificada de inhibidores de 3-hidroxi-3-metilglutaril-coenzima a reductasa.Info
- Publication number
- MX2010008466A MX2010008466A MX2010008466A MX2010008466A MX2010008466A MX 2010008466 A MX2010008466 A MX 2010008466A MX 2010008466 A MX2010008466 A MX 2010008466A MX 2010008466 A MX2010008466 A MX 2010008466A MX 2010008466 A MX2010008466 A MX 2010008466A
- Authority
- MX
- Mexico
- Prior art keywords
- modified release
- coa reductase
- reductase inhibitors
- hmg coa
- release formulations
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title abstract 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title abstract 2
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 title 1
- 230000000694 effects Effects 0.000 abstract 2
- 102000004316 Oxidoreductases Human genes 0.000 abstract 1
- 108090000854 Oxidoreductases Proteins 0.000 abstract 1
- 206010039020 Rhabdomyolysis Diseases 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 230000002440 hepatic effect Effects 0.000 abstract 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 231100000417 nephrotoxicity Toxicity 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invención se refiere a un dispositivo para la conformación o moldeo por explosión de piezas de trabajo, que comprende una cámara de ignición y un mecanismo de ignición, en donde un agente explosivo se puede encender en una ubicación de ignición en la cámara de ignición utilizando el mecanismo de ignición, y se proporciona una salida de la cámara de ignición, mejorado de tal modo que el mecanismo de ignición tenga una vida de servicio más larga. El objetivo se logra mediante un dispositivo en donde se proporciona un interruptor de impacto en la trayectoria (37) de propagación de la onda de detonación.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN145KO2008 | 2008-01-30 | ||
| PCT/IN2009/000069 WO2009095934A1 (en) | 2008-01-30 | 2009-01-30 | Modified release formulations of hmg coa reductase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2010008466A true MX2010008466A (es) | 2010-10-25 |
Family
ID=40638221
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010008466A MX2010008466A (es) | 2008-01-30 | 2009-01-30 | Formulaciones de liberación modificada de inhibidores de 3-hidroxi-3-metilglutaril-coenzima a reductasa. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20110003837A1 (es) |
| EP (1) | EP2285353A1 (es) |
| JP (1) | JP2011510974A (es) |
| AU (1) | AU2009208610A1 (es) |
| BR (1) | BRPI0906728A2 (es) |
| MX (1) | MX2010008466A (es) |
| WO (1) | WO2009095934A1 (es) |
| ZA (1) | ZA201006157B (es) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6642268B2 (en) * | 1994-09-13 | 2003-11-04 | G.D. Searle & Co. | Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors |
| CA2389616A1 (en) * | 1999-11-03 | 2001-05-10 | Howard J. Smith & Associates Pty Ltd. | Liver selective therapy |
| GB0001621D0 (en) * | 2000-01-26 | 2000-03-15 | Astrazeneca Ab | Pharmaceutical compositions |
| DE10209979A1 (de) * | 2002-03-07 | 2003-09-25 | Ratiopharm Gmbh | Arzneimittel mit Cholesterolspiegel-senkenden Wirkstoffen mit zeitverzögerter Wirkstofffreisetzung |
| GB0217306D0 (en) * | 2002-07-25 | 2002-09-04 | Novartis Ag | Compositions comprising organic compounds |
| US20050096391A1 (en) * | 2003-10-10 | 2005-05-05 | Per Holm | Compositions comprising fenofibrate and rosuvastatin |
| US8987322B2 (en) * | 2003-11-04 | 2015-03-24 | Circ Pharma Research And Development Limited | Pharmaceutical formulations for carrier-mediated transport statins and uses thereof |
| US20050147620A1 (en) * | 2004-01-05 | 2005-07-07 | Karl Bozicevic | Cinnamon formulation for reducing cholesterol and/or glucose levels |
| EP1968593B1 (en) * | 2005-12-20 | 2017-08-23 | LEK Pharmaceuticals d.d. | Pharmaceutical composition comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl-(3r,5s)-3,5-dihydroxyhept-6-enoic acid |
-
2009
- 2009-01-30 MX MX2010008466A patent/MX2010008466A/es not_active Application Discontinuation
- 2009-01-30 US US12/865,448 patent/US20110003837A1/en not_active Abandoned
- 2009-01-30 BR BRPI0906728-0A patent/BRPI0906728A2/pt not_active IP Right Cessation
- 2009-01-30 WO PCT/IN2009/000069 patent/WO2009095934A1/en active Application Filing
- 2009-01-30 AU AU2009208610A patent/AU2009208610A1/en not_active Abandoned
- 2009-01-30 EP EP09706394A patent/EP2285353A1/en not_active Withdrawn
- 2009-01-30 JP JP2010544844A patent/JP2011510974A/ja active Pending
-
2010
- 2010-08-27 ZA ZA2010/06157A patent/ZA201006157B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009095934A1 (en) | 2009-08-06 |
| BRPI0906728A2 (pt) | 2015-07-07 |
| EP2285353A1 (en) | 2011-02-23 |
| US20110003837A1 (en) | 2011-01-06 |
| ZA201006157B (en) | 2011-05-25 |
| AU2009208610A1 (en) | 2009-08-06 |
| JP2011510974A (ja) | 2011-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2008010921A3 (en) | Modulators of pharmacokinetic properties of therapeutics | |
| WO2006082523A3 (en) | Pharmaceutical sustained release composition of metformin | |
| WO2011142621A3 (en) | Pharmaceutical formulation in the form of bilayered tablets comprising hmg-coa reductase inhibitor and irbesartan | |
| GB2448224B (en) | Solid orally administered pharmaceutical composition for the reduction of side-effects of a dopaminergic agent | |
| MX2009008935A (es) | Moduladores de las propiedades farmacocineticas de productos terapeuticos. | |
| PT2038290E (pt) | Moduladores de receptor do tipo toll 7 | |
| WO2010136474A3 (en) | Substituted aminobutyric derivatives as neprilysin inhibitors | |
| WO2008038003A3 (en) | Pharmaceutical compositions of aripiprazole | |
| NZ599847A (en) | Pharmaceutical composition comprising a glp-1 agonist and methionine | |
| WO2009088414A3 (en) | Oral pharmaceutical dosage forms | |
| JOP20080499B1 (ar) | تراكيب صيدلية تعتمد على هيكليات فوقية للمواد المضادة لمستقبلات الانجيوتنسين ومثبطات الاندوبيبتيداز المتعادلة | |
| WO2006091575A3 (en) | Method of increasing drug oral bioavailability and compositions of less toxic orotate salts | |
| SI1718288T1 (sl) | Trdna formulacija ospemifena | |
| WO2008067257A8 (en) | Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme | |
| WO2012054831A3 (en) | Ready to use ketorolac formulations | |
| NZ600231A (en) | Pharmaceutical compositions comprising sigma receptor ligands | |
| TNSN06220A1 (en) | Benzimidazole derivatives | |
| WO2008011116A3 (en) | Aza-peptide protease inhibitors | |
| TN2013000257A1 (en) | Immunosuppressant formulations | |
| WO2007057221A3 (en) | Pharmaceutical compositions for the treatment of inflammatory and obstructive airways diseases | |
| WO2008062476A3 (en) | Pharmaceutical composition comprising rosuvastatin or pharmaceutically accepatble salts thereof | |
| WO2009066315A3 (en) | Sustained release compositions of trimetazidine and process for preparation thereof | |
| WO2008011117A3 (en) | Antiviral protease inhibitors | |
| WO2008008660A3 (en) | Cyclopentane derivatives as antiglaucoma agents | |
| UA95274C2 (ru) | Твердый фармацевтический препарат, содержащий ирбесартан, и способы его изготовления |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HH | Correction or change in general | ||
| FA | Abandonment or withdrawal |